<--- Back to Details
First PageDocument Content
Rare diseases / National Institutes of Health / Lysosomal storage disease / Blood–brain barrier / National Institute of Neurological Disorders and Stroke / Gene therapy / Alpha-mannosidosis / Biology / Medicine / Health
Date: 2010-04-26 15:39:48
Rare diseases
National Institutes of Health
Lysosomal storage disease
Blood–brain barrier
National Institute of Neurological Disorders and Stroke
Gene therapy
Alpha-mannosidosis
Biology
Medicine
Health

NNPDF-Funded Research Grant # 46 TITLE: Additional contribution to LSD Research Consortium for research into issues of common interest to all LSD support groups (See also Grant # 40) PROJECT INVESTIGATOR: Multiple PERIOD

Add to Reading List

Source URL: www.nnpdf.org

Download Document from Source Website

File Size: 201,35 KB

Share Document on Facebook

Similar Documents

How one patient with a rare disease coped with his genetic disorder

How one patient with a rare disease coped with his genetic disorder

DocID: 1r9mW - View Document

CrossMark_Color_flat+click

CrossMark_Color_flat+click

DocID: 1r0lC - View Document

What is  HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

What is HUNTER SYNDROME? Hunter syndrome, or mucopolysaccharidosis II (MPS II), is a rare and progressive lysosomal storage disease inherited in an X-linked recessive

DocID: 1lIxr - View Document

MUCOPOLYSACCHARIDOSES  Rare Diseases Unit of the Finnish Association of People with Physical Disabilities  Support for this guide was provided by Genzyme.

MUCOPOLYSACCHARIDOSES Rare Diseases Unit of the Finnish Association of People with Physical Disabilities Support for this guide was provided by Genzyme.

DocID: 1fJSQ - View Document

May 27, 2014  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

May 27, 2014 BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease Proprietary Glycosylation Independent Lysosomal Targeting (GILT) Tagging Technology Has Been Shown to Im

DocID: 1aiEg - View Document